Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial
Journal
The Lancet. Oncology
Journal Volume
13
Journal Issue
1
Date Issued
2012-01
Author(s)
Lehtinen, Matti
Paavonen, Jorma
Wheeler, Cosette M
Jaisamrarn, Unnop
Garland, Suzanne M
Castellsagué, Xavier
Skinner, S Rachel
Apter, Dan
Naud, Paulo
Salmerón, Jorge
Kitchener, Henry
Teixeira, Júlio C
Hedrick, James
Limson, Genara
Szarewski, Anne
Romanowski, Barbara
Aoki, Fred Y
Schwarz, Tino F
Poppe, Willy A J
De Carvalho, Newton S
Germar, Maria Julieta V
Peters, Klaus
Mindel, Adrian
De Sutter, Philippe
Bosch, F Xavier
David, Marie-Pierre
Descamps, Dominique
Struyf, Frank
Dubin, Gary
Abstract
Cervical intraepithelial neoplasia grade 2 or greater (CIN2+) is the surrogate endpoint used in licensure trials of human papillomavirus (HPV) vaccines. Vaccine efficacy against CIN3+, the immediate precursor to invasive cervical cancer, is more difficult to measure because of its lower incidence, but provides the most stringent evidence of potential cancer prevention. We report vaccine efficacy against CIN3+ and adenocarcinoma in situ (AIS) in the end-of-study analysis of PATRICIA (PApilloma TRIal against Cancer In young Adults).
Type
journal article